pipette
ESEspañol

Medication history, not clinical profiles, predicts antihypertensive treatment persistence across health systems

S. Wang, D. Lu, T. Tao

PreprintReal-world use

In the authors' words

Background. Hypertension control remains poor worldwide, in large part because patients discontinue antihypertensive treatment. Machine-learning (ML) prediction models for medication persistence are typically single-country and cross-sectional, rarely compared with simple clinical information, and lack external validation across health systems. Methods. We harmonized three prospective aging cohorts -- the China Health and Retirement Longitudinal Study (CHARLS), the Survey of Health, Ageing and Retirement in Europe (SHARE), and the US Health and Retirement Study (HRS) -- including adults aged >=50 years with doctor-diagnosed hypertension at baseline and known medication status at follow-up. We used baseline plus two prior waves to predict non-use of any antihypertensive medication at the next wave (treatment non-persistence), with 21 harmonized cross-sectional features, 11 longitudinal history features (including the prior non-use ratio), and a 3-feature parsimonious medication-history score (baseline non-use, prior non-use ratio, prior discontinuation). Models were L2-regularized logistic regression and random forest, evaluated by 5-fold x 5-repeat nested cross-validation and by direct transport of a CHARLS-trained model to SHARE and HRS without retraining. Three simple rule-based comparators were prespecified: baseline carry-forward (T0), prior non-use count (T1), and the 3-feature score (T2). Non-inferiority of T2 versus the full 32-feature logistic model was tested at delta=0.03 AUC. Country-level external validation across 18 SHARE countries used random-effects meta-analysis and inverse-variance meta-regression on World Bank indicators. Results. The analytic samples comprised 4,532 (CHARLS), 26,128 (SHARE) and 9,495 (HRS) participants, with non-persistence of 22.8%, 19.1% and 12.6%. Within each cohort, adding medication history raised AUC from 0.59-0.67 to 0.78-0.85 (Delta AUC 0.17-0.20; all 95% CIs >0). On direct transport, history models retained AUC 0.73-0.76 in SHARE and 0.83-0.85 in HRS, whereas cross-sectional models collapsed to near chance in SHARE (AUC 0.55-0.57). The baseline carry-forward rule alone achieved AUC 0.70-0.80; the 3-feature score achieved 0.75-0.83 and was non-inferior to the full logistic model (Delta AUC <=0.027; upper CI bounds <0.03) in all three within-cohort comparisons and both transport targets. Across 18 European countries, cross-sectional models pooled at 0.55 (I^2=30%) while history models pooled at 0.74-0.76 (I^2=82-88%); transported AUC increased with national wealth (r=0.58, P=0.011), and calibration slope declined with non-persistence burden (r=-0.69, P=0.002) and out-of-pocket expenditure share (r=-0.51, P=0.032). Conclusions. A parsimonious medication-history core transfers across health systems, whereas cross-sectional clinical profiles do not. Complex ML adds little beyond a one-question or three-variable medication-history rule. Discrimination is strongest in high-resource, low-burden systems, but probability calibration degrades where non-persistence is common, requiring local recalibration before individual-level use.

Main resultLimitation the authors admit

Appeared: Thursday, November 5. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.02.26367145